

Cardiac Resynchronization Therapy Market Size to Surpass Around USD \$983.3 Million by 2027 | CAGR 4.9%

U.S. cardiac resynchronization therapy market size was valued at \$965.6 Mn in 2019, and is projected to reach \$983.3 million by 2027, registering a CAGR of 4.9%

PORTLAND, OREGON, UNITED STATES, August 26, 2022 /EINPresswire.com/ -- Rise in the geriatric population, increase in the prevalence of cardiovascular diseases, and development in healthcare infrastructure have boosted the growth of the U.S. [cardiac resynchronization therapy market](#). Moreover, high-end technological developments in CRT devices supplemented the market growth. However, product recalls in the U.S., cost of CRT devices, and shortage of healthcare professionals hinder the market growth. On the contrary, developing opportunities in the low economic U.S. states would open lucrative opportunities for the market players.

The U.S. cardiac resynchronization therapy market size was valued at \$965.6 million in 2019, and is projected to reach \$983.3 million by 2027, registering a CAGR of 4.9% from 2020 to 2027.

Download Sample Report at: <https://www.alliedmarketresearch.com/request-sample/10657>

Cardiac resynchronization therapy is a treatment for heart failure in patients with abnormal ventricular contraction. Heart muscles weaken due to heart failure resulting in inadequate blood pumping to other body parts and fluid accumulation begins in lungs and legs. This condition worsens if ventricles aren't synced with each other while beating. Cardiac resynchronization therapy (CRT) is a procedure to implant a device called a biventricular pacemaker (also called a cardiac resynchronization device) in chest to improvise contraction of heart chambers and make it normal. Pacemaker sends electrical signals to both ventricles. These signals trigger the ventricular contraction to be in coordination and improves the blood pumping as well. Often, pacemaker also contains an implantable cardioverter-defibrillator (ICD), which can deliver an electrical shock to reset the heartbeat, in situations where heart rhythm becomes extremely erratic. Cardiac resynchronization therapy also aids in reduction of symptoms of heart failure and lower your risk of heart failure and related complications, including death. Clinical studies also suggest that CRT decreases hospitalization and morbidity as well as improves in quality of life for the heart failure patients.

COVID-19 scenario analysis:

Due to the COVID – 19 outbreak, majority of healthcare, pharmaceutical and biotechnology organizations have concentrated on treatment therapies and medication against Novel coronavirus, the medical professionals are engaged in providing COVID-19 related services, unavailability of experts to treat patients suffering from cardiac arrests

As a result, other healthcare segments have to face negligence

Furthermore, it has been observed after some research that people with prevalence of cardiac diseases are at higher risk for mortality and morbidity related to COVID-19 compared to the average population

Recent studies have also revealed that COVID-19 can cause heart injury, even in people without heart abnormalities

Henceforth, patients and the cardiac arrest treatment industry is facing struggles amid COVID-19 pandemic

However, the demand for CRT and associated medical devices, especially pacemakers amidst COVID-19 pandemic is soaring in order to reduce the risk of systolic dysfunction, dyssynchronous ventricular contraction and ventricular arrhythmias which leads to an increase in the risk of cardiac failure

The U.S. cardiac resynchronization therapy market is segmented on the basis of CRT pacemaker segment is estimated to manifest the highest CAGR of 5.7% during the forecast period. However, the CRT defibrillator segment held the largest share in 2019, accounted for more than four-fifths of the market.

Enquiry for Short-term and Long-term Impacts of COVID-19 at:
<https://www.alliedmarketresearch.com/purchase-enquiry/10657>

Based on end user, the specialized cardiac treatment centers segment is estimated to register the highest CAGR of 6.0% during the forecast period. However, the hospitals segment held the largest share in 2019, accounting for more than three-fifths of the market.

The U.S. cardiac resynchronization therapy market report includes an in-depth analysis of the major market players such as Abbott Laboratories, Osypka Medical GmbH, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Medtronic plc, LivaNova PLC, MEDICO S.p.A., MicroPort Scientific Corporation, OSCOR Inc., and Lepu Medical Technology (Beijing) Co., Ltd.

We also Offers Regional and Country Reports-

Japan Cardiac Resynchronization Therapy Market

South Korea Cardiac Resynchronization Therapy Market

Singapore Cardiac Resynchronization Therapy Market
China Cardiac Resynchronization Therapy Market
Indonesia Cardiac Resynchronization Therapy Market
Australia Cardiac Resynchronization Therapy Market
Taiwan Cardiac Resynchronization Therapy Market

"We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market."

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI

David Correa
Allied Analytics LLP
800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/587920646>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.